本文就中药材及饮片在栽培、采收加工、饮片生产、流通、监管等方面的现状进行了描述，对其中可能造成中药材质量问题的原因进行了分析，并在此基础上提出了解决的想法。笔者认为建立种源中心、从中药材栽培、产地加工及饮片生产均采用集约化的管理经营模式，可以很大程度地减少中药材生产各环节的不确定因素，保证药材质量。此外，我们建议修改某些品种药材的药典标准，使其更适用于目前市场情况，有利于提高市售药材质量。最后认为中药材作为一种药品，从栽培到生产的全过程应统一于国家食品药品监督管理局 下管理，才更有利于药材的溯源及全产业链的质量监控。

This paper described the present situation of Chinese medicinal materials and their slices in terms of cultivation, harvest, slices process, circulation, surpervision, listed the possible reasons for quality reduction of Chinese medicinal materials, and proposed solutions based on the situation. We believe that the significant improvement in the quality of Chinese medicinal materials (slices) is viable by decreasing the uncertainties during manufacture process, which could be accomplished by establishing the intensive management of medicinal material cultivation, harvest and slice production process. Besides, the revision of Pharmacopeia standards for TCM was requested for better application in current market and for production property improvement. Finally, as a kind of medicine, traditional Chinese medicinal materials should be unified under SFDA during the whole process of production, which is more conducive to medicinal materials traceability and quality monitoring within the whole industrial chain.

辽宁省东北道地药材研发重点实验室（辽科发[2011]20号），主持人：殷军